Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hwa-ping Feng

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2026
Prostatic tissue distribution of gepotidacin in patients undergoing prostatectomy: an ex-vivo microdialysis and pharmacokinetic modelling studyValentin Al Jalali, Vincent Aranzana-Climent, Anselm Jorda, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
European Journal of Drug Metabolism and Pharmacokinetics|December 17, 2017
Pharmacokinetics, Safety, and Tolerability of Single-Dose Elbasvir in Participants with Hepatic ImpairmentWilliam L Marshall, Hwa-Ping Feng, Larissa Wenning, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2026
Prostatic tissue distribution of gepotidacin in patients undergoing prostatectomy: an ex-vivo microdialysis and pharmacokinetic modelling studyValentin Al Jalali, Vincent Aranzana-Climent, Anselm Jorda, et al.
Antimicrobial Agents and Chemotherapy|February 13, 2019
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine Fandozzi, et al.
Pageof 4